Supplementary Data from TBK1 is a Synthetic Lethal Target in Cancer with vhl Loss

Lianxin Hu,Haibiao Xie,Xijuan Liu,Frances Potjewyd,Lindsey I. James,Emily M. Wilkerson,Laura E. Herring,Lihua Xie,Xian Chen,Johnny Castillo Cabrera,Kai Hong,Chengheng Liao,Xianming Tan,Albert S. Baldwin,Kan Gong,Qing Zhang

DOI: https://doi.org/10.1158/2159-8290.22535705.v1

2023-01-01

Abstract:Extended methods and supplementary figures

What problem does this paper attempt to address?

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Data from TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss

Lianxin Hu,Haibiao Xie,Xijuan Liu,Frances Potjewyd,Lindsey I. James,Emily M. Wilkerson,Laura E. Herring,Ling Xie,Xian Chen,Johnny Castillo Cabrera,Kai Hong,Chengheng Liao,Xianming Tan,Albert S. Baldwin,Kan Gong,Qing Zhang

DOI: https://doi.org/10.1158/2159-8290.c.6547922

2023-01-01

Abstract:AbstractTANK binding kinase 1 (TBK1) is an important kinase involved in the innate immune response. Here we discover that TBK1 is hyperactivated by von Hippel-Lindau (VHL) loss or hypoxia in cancer cells. Tumors from patients with kidney cancer with VHL loss display elevated TBK1 phosphorylation. Loss of TBK1 via genetic ablation, pharmacologic inhibition, or a new cereblon-based proteolysis targeting chimera specifically inhibits VHL-deficient kidney cancer cell growth, while leaving VHL wild-type cells intact. TBK1 depletion also significantly blunts kidney tumorigenesis in an orthotopic xenograft model in vivo. Mechanistically, TBK1 hydroxylation on Proline 48 triggers VHL as well as the phosphatase PPM1B binding that leads to decreased TBK1 phosphorylation. We identify that TBK1 phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation. Our results establish that TBK1, distinct from its role in innate immune signaling, is a synthetic lethal target in cancer with VHL loss.Significance:The mechanisms that lead to TBK1 activation in cancer and whether this activation is connected to its role in innate immunity remain unclear. Here, we discover that TBK1, distinct from its role in innate immunity, is activated by VHL loss or hypoxia in cancer.See related commentary by Bakouny and Barbie, p. 348.This article is highlighted in the In This Issue feature, p. 327
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Yufei Wang,Man Zhao,Lina Zhao,Yu Geng,Guanghao Li,Lin Chen,Jingxuan Yu,Hongfeng Yuan,Huihui Zhang,Haolin Yun,Ying Yuan,Guowen Wang,Jinyan Feng,Liang Xu,Shuai Wang,Chunyu Hou,Guang Yang,Ningning Zhang,Wei Lu,Xiaodong Zhang

DOI: https://doi.org/10.1158/0008-5472.22433561.v1

2023-01-01

Abstract:Supplementary materials and methods, Supplementary figures, Supplementary figure legends, Supplementary tables
TBK1 is a Synthetic Lethal Target in Cancer with VHL Loss

Lianxin Hu,Haibiao Xie,Xijuan Liu,Frances Potjewyd,Lindsey James,Emily M. Wilkerson,Laura E. Herring,Ling Xie,Xian Chen,Johnny Castillo Cabrera,Kai Hong,Chengheng Liao,Xianming Tan,Albert S. Baldwin,Kan Gong,Qing Zhang

DOI: https://doi.org/10.1158/2159-8290.cd-19-0837

2020-01-01

Abstract:TANK binding kinase 1 (TBK1) is an important kinase involved in the innate immune response. Here we discover that TBK1 is hyperactivated by von Hippel-Lindau (VHL) loss or hypoxia in cancer cells. Tumors from patients with kidney cancer with VHL loss display elevated TBK1 phosphorylation. Loss of TBK1 via genetic ablation, pharmacologic inhibition, or a new cereblon-based proteolysis targeting chimera specifically inhibits VHL-deficient kidney cancer cell growth, while leaving VHL wild-type cells intact. TBK1 depletion also significantly blunts kidney tumorigenesis in an orthotopic xenograft model in vivo. Mechanistically, TBK1 hydroxylation on Proline 48 triggers VHL as well as the phosphatase PPM1B binding that leads to decreased TBK1 phosphorylation. We identify that TBK1 phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation. Our results establish that TBK1, distinct from its role in innate immune signaling, is a synthetic lethal target in cancer with VHL loss. SIGNIFICANCE: The mechanisms that lead to TBK1 activation in cancer and whether this activation is connected to its role in innate immunity remain unclear. Here, we discover that TBK1, distinct from its role in innate immunity, is activated by VHL loss or hypoxia in cancer.See related commentary by Bakouny and Barbie, p. 348.This article is highlighted in the In This Issue feature, p. 327.
Supplementary Figure 2 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Mark L. McCleland,Adam S. Adler,Yongfeng Shang,Thomas Hunsaker,Tom Truong,David L. Peterson,Eric Torres,Li,Benjamin Haley,Jean-Philippe Stéphan,Marcia Belvin,Georgia Hatzivassiliou,Elizabeth M. Blackwood,Laura Corson,Marie Evangelista,Jiping Zha,Ron Firestein

DOI: https://doi.org/10.1158/0008-5472.22394613.v1

2023-01-01

Abstract:PDF file - 257K, Animal weight change and tumor volume of individual xenograft tumors
Supplementary Information from A Combinatorial Strategy for Targeting &Lt;i>brafv600e-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

Chandra Kanta Ghosh,Suresh Kumar,Yevgeniya Kushchayeva,Kelli Gaskins,Myriem Boufraqech,Darmood Wei,Sudheer Kumar Gara,Lisa Zhang,Yaqin Zhang,Min Shen,Sanjit Mukherjee,Electron Kebebew

DOI: https://doi.org/10.1158/1078-0432.22475603.v1

2023-01-01

Abstract:Supplementary method and data
Supplementary Figures from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Rongqing Pan,Leah J. Hogdal,Juliana M. Benito,Donna Bucci,Lina Han,Gautam Borthakur,Jorge Cortes,Daniel J. DeAngelo,LaKeisha Debose,Hong Mu,Hartmut Döhner,Verena I. Gaidzik,Ilene Galinsky,Leonard S. Golfman,Torsten Haferlach,Karine G. Harutyunyan,Jianhua Hu,Joel D. Leverson,Guido Marcucci,Markus Müschen,Rachel Newman,Eugene Park,Peter P. Ruvolo,Vivian Ruvolo,Jeremy Ryan,Sonja Schindela,Patrick Zweidler-McKay,Richard M. Stone,Hagop Kantarjian,Michael Andreeff,Marina Konopleva,Anthony G. Letai

DOI: https://doi.org/10.1158/2159-8290.22530759

2023-01-01

Abstract:PDF file 433K, This includes supplemental figures referenced in the article text
Supplementary Figure 1 from Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer

Tong Sun,Yifeng Zhou,Ming Yang,Zhibin Hu,Wen Tan,Xiaohong Han,Yuankai Shi,Jiarui Yao,Yongli Guo,Dianke Yu,Tian Tian,Xiaoyi Zhou,Hongbing Shen,Dongxin Lin

DOI: https://doi.org/10.1158/0008-5472.22376705.v1

2023-01-01

Abstract:Supplementary Figure 1 from Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
Supplementary Data from TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling

Xinchao Zhang,Shuyan Li,Jianxing He,Yunjie Jin,Ruonan Zhang,Wen‐Kui Dong,Min Lin,Yajing Yang,Tongguan Tian,Yuefan Zhou,Yixin Xu,Qun-Ying Lei,Jing Zhang,Qing Zhang,Yang Xu,Lei Lv

DOI: https://doi.org/10.1158/0008-5472.22431241

2023-01-01

Abstract:Supplementary Data from TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling
Supplementary Figure 1 from Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer

Tong Sun,Yifeng Zhou,Ming Yang,Zhibin Hu,Wen Tan,Xiaohong Han,Yuankai Shi,Jiarui Yao,Yongli Guo,Dianke Yu,Tian Tian,Xiaoyi Zhou,Hongbing Shen,Dongxin Lin

DOI: https://doi.org/10.1158/0008-5472.22376705

2023-01-01

Abstract:Supplementary Figure 1 from Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
Supplementary Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma

Cho-Hao Lin,Khadija H. Elkholy,Nissar Ahmad Wani,Li Ding,Ping Hu,Juan M. Barajas,Lianbo Yu,Xiaoli Zhang,Samson T. Jacob,Wasif N. Khan,Xuefeng Bai,Anne M. Noonan,Kalpana Ghoshal

DOI: https://doi.org/10.1158/1535-7163.22506318

2023-01-01

Abstract:Supplementary figures and tables
Supplementary Data from Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis

Rui Jin,Boxuan Liu,Xiuju Liu,Yijian Fan,Wei Peng,Chunzi Huang,Adam Marcus,Gabriel Sica,Melissa Gilbert-Ross,Yuan Liu,Wei Zhou

DOI: https://doi.org/10.1158/1535-7163.22520611

2023-01-01

Abstract:Supplemental Figures and Tables
Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Cuicui Liu,Jiankun Qiang,Qiaodan Deng,Jie Xia,Lu Deng,Lei Zhou,Dong Wang,Xueyan He,Ying Liu,Botao Zhao,Jinhui Lv,Zuoren Yu,Qun-Ying Lei,Zhi-Ming Shao,Xiao-Yong Zhang,Lixing Zhang,Suling Liu

DOI: https://doi.org/10.1158/0008-5472.22429821.v1

2023-01-01

Abstract:Supplementary Methods, Figures and Figure legends
Supplementary Figure 6 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Mark L. McCleland,Adam S. Adler,Yongfeng Shang,Thomas Hunsaker,Tom Truong,David L. Peterson,Eric Torres,Li,Benjamin Haley,Jean‐Philippe Stephan,Marcia Belvin,Georgia Hatzivassiliou,Elizabeth M. Blackwood,Laura Corson,Marie Evangelista,Jiping Zha,Ron Firestein

DOI: https://doi.org/10.1158/0008-5472.22394601.v1

2023-01-01

Abstract:PDF file - 6626K, Validation of IHC antibody specificity for LDHB, LDHA, MCT1, and MCT4
Supplementary Data from CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma

Jingshu Xiao,Jiaming Liang,Junjie Fan,Panpan Hou,Xiaodong Li,Haipeng Zhang,Kai Li,Lang Bu,Ping Li,Miao He,Yongheng Zhong,Liping Guo,Penghui Jia,Qiaoqiao Xiao,Junyu Wu,Hong Peng,Chunmei Li,Fan Xing,Deyin Guo

DOI: https://doi.org/10.1158/0008-5472.22431786.v1

2023-01-01

Abstract:Supplementary Data from CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma
Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429084.v1

2023-01-01

Abstract:Supplementary materials including tables, figures, and detailed methods.
Supplementary Figure Legend, Table 1 from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Fabrice André,Thomas Bachelot,Mario Campone,Florence Dalenc,Jose M. Perez-Garcia,Sara A. Hurvitz,Nicholas Turner,Hope Rugo,John W. Smith,Stephanie Deudon,Michael Shi,Yong Zhang,Andrea Kay,Diana Graus Porta,Alejandro Yovine,José Baselga

DOI: https://doi.org/10.1158/1078-0432.22451297.v1

2023-01-01

Abstract:PDF file - 61K, Growth Inhibition in FGFR1- and FGFR2-Amplified Cell Lines.
Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Jennifer R. Devlin,Katherine M. Hannan,Nadine Hein,Carleen Cullinane,Eric Kusnadi,Pui Yee Ng,Amee J. George,Jake Shortt,Megan J. Bywater,Gretchen Poortinga,Elaine Sanij,Jian Kang,Denis Drygin,Sean O'Brien,Ricky W. Johnstone,Grant A. McArthur,Ross D. Hannan,Richard B. Pearson

DOI: https://doi.org/10.1158/2159-8290.22530950

2023-01-01

Abstract:This figure shows supplementary data pertinent to Figure 4 including protein and cell death analysis data.

Supplementary Data from TBK1 is a Synthetic Lethal Target in Cancer with <i>vhl</i> Loss

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Data from TBK1 Is a Synthetic Lethal Target in Cancer with <i>VHL</i> Loss

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

TBK1 is a Synthetic Lethal Target in Cancer with VHL Loss

Supplementary Figure 2 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Supplementary Information from A Combinatorial Strategy for Targeting &Lt;i>braf</i><sup>v600e</sup>-Mutant Cancers with BRAF<sup>V600E</sup> Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

Supplementary Figures from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Supplementary Figure 1 from Functional Genetic Variations in <i>Cytotoxic T-Lymphocyte Antigen 4</i> and Susceptibility to Multiple Types of Cancer

Supplementary Data from TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling

Supplementary Figure 1 from Functional Genetic Variations in <i>Cytotoxic T-Lymphocyte Antigen 4</i> and Susceptibility to Multiple Types of Cancer

Supplementary Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma

Supplementary Data from Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis

Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Supplementary Figure 6 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Supplementary Data from CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma

Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Figure Legend, Table 1 from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Supplementary Data from TBK1 is a Synthetic Lethal Target in Cancer with &lt;i&gt;vhl&lt;/i&gt; Loss

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Data from TBK1 Is a Synthetic Lethal Target in Cancer with <i>VHL</i> Loss

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

TBK1 is a Synthetic Lethal Target in Cancer with VHL Loss

Supplementary Figure 2 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Supplementary Information from A Combinatorial Strategy for Targeting &Lt;i&gt;braf&lt;/i&gt;&lt;sup&gt;v600e&lt;/sup&gt;-Mutant Cancers with BRAF&lt;sup&gt;V600E&lt;/sup&gt; Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

Supplementary Figures from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Supplementary Figure 1 from Functional Genetic Variations in <i>Cytotoxic T-Lymphocyte Antigen 4</i> and Susceptibility to Multiple Types of Cancer

Supplementary Data from TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling

Supplementary Figure 1 from Functional Genetic Variations in &lt;i&gt;Cytotoxic T-Lymphocyte Antigen 4&lt;/i&gt; and Susceptibility to Multiple Types of Cancer

Supplementary Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma

Supplementary Data from Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis

Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Supplementary Figure 6 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Supplementary Data from CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma

Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Figure Legend, Table 1 from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Supplementary Data from TBK1 is a Synthetic Lethal Target in Cancer with <i>vhl</i> Loss

Supplementary Information from A Combinatorial Strategy for Targeting &Lt;i>braf</i><sup>v600e</sup>-Mutant Cancers with BRAF<sup>V600E</sup> Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

Supplementary Figure 1 from Functional Genetic Variations in <i>Cytotoxic T-Lymphocyte Antigen 4</i> and Susceptibility to Multiple Types of Cancer